Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
17 January 2014 No. 02 BLUNTING THE INTUBATION RESPONSE: FACT OR FICTION K Purchase Moderator: C Evans Discipline of Anaesthetics CONTENTS MECHANISM OF THE INTUBATION RESPONSE............................................... 4 BLUNTING THE HAEMODYNAMIC RESPONSE ................................................ 7 LIGNOCAINE........................................................................................................ 7 OPIOIDS ............................................................................................................... 8 α 2 AGONISTS ................................................................................................... 10 β BLOCKERS ..................................................................................................... 11 MAGNESIUM SULPHATE (MGSO4) .................................................................. 12 NOVEL IDEAS .................................................................................................... 13 SUMMARY OF EVIDENCE................................................................................. 15 BENEFITS OF ATTENUATING THE RESPONSE ............................................. 17 CONCLUSION .................................................................................................... 20 REFERENCES.................................................................................................... 21 Page 2 of 26 OBJECTIVES Discuss the mechanism of the intubation response Explore the various pharmacological methods to attenuate the intubation the response Attempt to determine the benefits of blunting the intubation response Page 3 of 26 BLUNTING THE INTUBATION RESPONSE: FACT OR FICTION INTRODUCTION Laryngoscopy and tracheal intubation are noxious stimuli associated with a transient increase in autonomic response. King et al described this response more than 60 years ago.(1) It is most often associated with an increase in heart rate and blood pressure and is thought to be of little consequence in the healthy individual but could be deleterious in the vulnerable patient.(2) This response varies with depth of anaesthesia, duration and difficulties during laryngoscopy and intubation, and certain patient factors including history of diabetes(3) and cardiovascular disease(4)(5) MECHANISM OF THE INTUBATION RESPONSE Basic anatomy: Figure 1: the sensory innervation of the airways(6) The pharynx: sensory innervation – Glossopharyngeal nerve supplies the posterior third of the tongue, the fauces and tonsillae, anterior epiglottis and all parts of the pharynx with visceral sensory fibers.Motor innervation- the pharynx receives efferent supply from the vagus nerve through its pharyngeal branch.(6) Page 4 of 26 The larynx: sensory innervation – the internal laryngeal nerve, branch of the superior laryngeal nerve, provides sensory supply from the posterior epiglottis to the vocal cords. The recurrent laryngeal nerve supplies the larynx below the vocal cords and the trachea. Motor innervation: the recurrent laryngeal nerve supplies all intrinsic muscles of the larynx except the cricothyroid muscles. (6) Figure 2: innervation of the larynx (7) Simply put, with regards to sensory innervation, the oropharynx, posterior third of the tongue and anterior part of the epiglottis are supplied by glossopharyngeal. The posterior epiglottis and distal airway structures are supplied by branches of the vagus nerve. Mechanism of the intubation response The precise mechanism of the intubation response (IR) is elusive but it has been established that it has both a sympathetic and parasympathetic element. The effect is transient occurring 30 seconds after intubation and lasting for less than 10 minutes thereafter.(8) The sympathetic response is a polysynaptic pathway with the glossopharyngeal and vagus nerve forming the afferent arc to the sympathetic nervous system via the brain stem and spinal cord. This ensures a diffuse autonomic response at the efferent side including increased firing of the cardioaccelerator fibres and release of adrenergic mediators including norepinephrine, epinephrine and vasopressin. Page 5 of 26 The net effect of this autonomic surge is an increased Blood pressure (BP), heart rate (HR), pulmonary artery wedge pressure and decreased ejection fraction. The parasympathetic reflex is monosynaptic and more common in children but can occur in some adults. The reflex is mediated by increased vagal tone at the SA node. (2) The haemodynamic response to laryngeal and endo- tracheal intubation (LETI) is transient and in most patients thought to be of little consequence. In patients with coronary artery disease (CAD), hypertension, raised intra cranial or intra ocular pressure it may be associated with myocardial ischaemia, infarction, arrhythmias, cardiac failure, pulmonary oedema and cerebral haemorrhage. (5) The process of intubation comprises of different phases and these affect the haemodynamic response differently. Orotracheal intubation consists of 2 phases: direct laryngoscopy and passing of endotracheal tube through the vocal cords and trachea. (9) Four studies looked at this differential effect. Sing(9), Shinji(10) and Hassan(11) concur that tracheal intubation and cuff inflation produce a substantial haemodynamic effect, significantly greater than laryngoscopy alone. Shribman(12) however found that orotracheal intubation did not significantly contribute to the haemodynamic effect. These studies give the impression that greatest increase in HR occurs during LETI and greatest increase in BP occurs during laryngoscopy. With no active attempt at blunting this haemodynamic response, increases in SBP of 41-53 mmHg, HR 20-23 and MAP of up to 100% above baseline have been documented.(1)(13) Page 6 of 26 BLUNTING THE HAEMODYNAMIC RESPONSE The possibilities to offset or blunt the intubation response are numerous. Options include pharmacological, peripheral blocks and variations in techniques including various blades and conduits for intubations. This booklet will only focus on pharmacological techniques. Pharmacological options: Local anaesthetics Opioids α 2 agonists β 2 blockers MgSO4 Gabapentin, pregabalin LIGNOCAINE: The effectiveness of lignocaine to blunt the intubation response (IR) is contentious. Numerous studies dating from 1960 have looked at different doses, timing and routes of administering Lignocaine. From the discussion above on the nerve supply of the larynx and the effect that tracheal intubation has on the IR it is apparent why laryngeal tracheal routes will not entirely blunt the response.(14)(15) Hamill et al and Laurito et al both looked at the IV route of Lignocaine to blunt the response to LETI. Hamill (14) used a dose of 1.5mg/kg, ivi 1minute prior to LETI and compared this to 4ml of a 4% solution sprayed laryngealtracheally. The group that received topical lignocaine sustained significant increase in HR and BP after LETI that lasted for more than 2 minutes. The authors note that the IV route did not completely attenuate the response as there was still significant increase in BP and HR although only sustained for 1 minute or less. Laurito et al(16) compared IV Lignocaine (2mg/kg) 1 minute pre LETI to nebulized lignocaine 4mg/kg 15 minutes prior to LETI. Within each group all haemodynamic variables increased significantly. With mean arterial pressures of 140mmHg recorded. Miller et al(17) also failed to demonstrate that Lignocaine attenuates the haemodynamic response to LETI. They studied Lignocaine 1.5mg ivi given 1,2 and 3 minutes prior to LETI. Sklar et al (18)found that aerosol application of lignocaine 120mg was effective in attenuating the both the BP and HR response in adults. This was applied for 5 minutes duration and 8.5 min prior to induction. Various other studies support the use of Lignocaine 1,5mg/kg ivi given between 24 minutes to attenuate the response. Tam et al(19) and Splinter et al(20) could only demonstrate benefit with regards to the BP response, however Helfman(21) found a dose of 1,5 mg/kg, given 2 minutes prior to LETI, to blunt both the BP and HR response. The principal limitation when comparing studies is heterogeneity of the studies. Various doses, timings, pre medications and induction agents are used. Page 7 of 26 At best, intra venous Lignocaine will occasionally blunt the BP response and almost never the HR response. If administered it should be at a dose of 1,5mg/kg, 3 minutes prior to intubation.(2) Topical routes are not effective in blunting the intubation response and few studies have shown convincing benefit of the aerosol route.(22) OPIOIDS The addition of opioids deepens the level of anaesthesia and therefor decreases the sympathetic outflow. Alfentanil: numerous studies show that a dose of 30µg/kg given between 1.5 and 2 minutes prior to intubation provides complete attenuation of the haemodynamic response.(23)(24)(25)(26) Lower dosages, 15µg/kg, seem to attenuate the BP response but not the HR response.(26) In the elderly 10µg/kg given 3-4 minutes pre induction has also been shown to completely blunt the haemodynamic response.(27) Higher dosages have been associated with bradycardia and hypotension.(23) Few studies distinguish between hypertensive and non-hypertensive patients. Only Miller(25) et al used patients from ASA 1-3 stages but did not specify the reason for the staging. A dose of Alfentanil 10µg/kg given over 30 seconds has been suggested to be effective in blunting the cardiovascular effect in hypertensive patients on long term treatment. In this study 3/20 patients developed hypotension requiring Ephedrine.(28) Remifentanil: The rapid onset and short duration of Remifentanil makes it an attractive drug for attenuating the IR. Thompson et al(29) initially found that a dose of 1µg/kg followed by and infusion of 0.5µg/kg/min attenuated the haemodynamic response in healthy adults. This dose was associated with profound bradycardia and hypotension in half the patients. A subsequent study(30) indicated that 0.5µg/kg followed by an infusion of 0.25µg/kg/min was as effective in blunting the response with no incidence of bradycardia or hypotension requiring treatment. They also indicate that at the higher doses, pre-treatment with glycopyrrolate 200µg, decreases the incidence of side effects. Page 8 of 26 Maguire et al (28)demonstrated that a bolus dose of 0.5µg/kg followed by infusion at 0.1µg/kg/min effectively reduces the response to LETI in hypertensive patients on treatment. Of note is that all patients were pre-treated with glycopyrrolate 200 µg. None of the patients developed a bradycardia but 7/20 patients required rescue medication for hypotension. (SBP 80-100 mmHG). Most studies agree that a dose of 2µg/kg significantly reduces the BP and HR and that this dose is not recommended for the elderly or compromised patient.(22) Hart et al(31) compared Remifentanil ( 0.5µg/kg followed by an infusion of 0.1µg/kg/min) and Alfentanil ( 10µg/kg) in elderly patients. The study included patients of ASA I-III but excluded patients with evidence of cardiovascular disease. They concluded that both drugs similarly attenuated the haemodynamic response but that the incidence of hypotension in both groups justifies caution in the elderly. Fentanyl: Numerous studies have looked at various doses and timing to administer Fentanyl and its effect on the intubation response. Unsurprisingly, high doses of 50-75µg/kg completely blunt the response but are associated with significant side effects. (2) In normotensive ASA I/II patients various authors indicate that a dose of 2µg/kg given between 3,5-5 min pre LETI suppress the response. (32)(33) Kautto et al (34) and Feng at al (33) indicated that although the BP response was attenuated at this dose, the HR response was not sufficiently obtunded. Others indicate that a dose of 5-8µg/kg given between 3,5-5 min pre LETI completely blunts the response. (34)(35)(36) In elderly patients a dose of 3µ/kg has been indicated to prevent a haemodynamic response.(37) Again, most studies are heterogenic and difficult to compare. Dosages that seem to be most effective are between 5-6µg/kg given 3-5 minutes prior to LETI. Dose reduction is prudent in the elderly. With these doses there is a risk for complications including respiratory depression and delayed awakening in short cases.(2) Sufentanil: The use of Sufentanil has been researched extensively in the paediatric population but research in the adult population appears scanty. Kay et al reported a dose of 0,5-1µg/kg given 2 minutes pre LETI sufficiently blocked the response in adults.(38) Zhang et al(39) reported that in patients for heart valve replacement, a dose of 1µg/kg sufficiently blocked the BP and HR response. A dose of 1.5µg/kg was associated with significant bradycardia requiring Atropine administration in 27% of cases. Page 9 of 26 In two comparable studies in normotensive ASA I-III patients, a bolus dose of 0.1µg/kg followed by an infusion of 0.01µg/kg/min for 5 minutes prior to LETI was effective in blunting both the BP and HR response.(40)(41) In children, a dose between 0.2-0.3µg/kg administered 2 min prior to LETI has been found to significantly attenuate the haemodynamic response to intubation.(42)(43) None of the children in the higher range group experienced significant side effects requiring treatment. α 2 AGONISTS Stimulation of the presynaptic α receptors leads to reduced secretion of noradrenaline and renin. Vagotonic effects that decrease the HR are also present. Most of the studies compare Clonidine as a premedication to various methods of anaesthesia that included variable doses of Fentanyl and Alfentanil. Studies indicate that, used in addition to a standard general anaesthetic, Clonidine 4-5µg/kg po given between 60-90 minutes prior to surgery can be beneficial. Benefits include reduced doses of opioids and induction agents, decreased haemodynamic response to LETI and improved intraoperative haemodynamics. The risk of bradycardia is always present and was treated with Atropine in some of the studies.(44)(45)(46)(47)(48) Drawbacks of Clonidine include long duration of onset, prolonged duration of action and therefore the risk of post-operative sedation in short procedures as well as the risk of hypotension and bradycardia.(2)(44) Dexmedetomidine is a highly selective α2 agonist. A biphasic cardiovascular response has been described. After a bolus of 1µg/kg, a transient increase in BP and decrease in HR is seen. This is thought to be due to stimulation of α2 receptors in vascular smooth muscle. The vasoconstriction effect thus appears before the central effects. This response can be decreased but not completely avoided by giving the bolus dose as an infusion over 10 minutes.(49) Aho et al (50) showed in healthy patients a bolus infusion of 0.12µg/kg over 10 min followed by an infusion of 0.006µg/kg significantly reduced the HR but not the BP response to LETI. Of note is that 40% of the patients in the Dexmedetomidine group required Atropine to treat bradycardia. Jaakola et al (51) found an infusion of 0.6µg/kg/min 10 minutes prior to LETI reduced the BP and HR response in patients presenting for ophthalmic surgery. Bajwa et al(52) indicated that an infusion of 1µg/kg over 20 minutes attenuated but did not completely obtund the response to LETI. None of the patients in this study had a significant bradycardiac or hypotensive episode however only healthy ASA I patients were included. Page 10 of 26 Menda et al investigated patients undergoing fast track CABG surgery. An infusion of 1µg/kg was given over 15 minutes. This was compared to a placebo group. Their conclusion was that Dexmedetomidine can safely be used to attenuate the haemodynamic response. The incidence of hypertension post intubation in the placebo group was statistically significant. The incidence of hypotension was not statistically significantly between the 2 groups. (53) Sulaiman et al(54) confirm these results but at much lower doses. 60 patients for off pump CABG were randomly allocated to a Dexmedetomidine group or placebo group. An infusion of 0.5µg/kg over 10 minutes found better haemodynamic control post LETI in the Dexmedetomidine group. No adverse effects needing treatment were observed. Significantly, almost 50% of the patients in each group were on β-blockers pre-operatively. In summary, from the above studies, it appears that doses between 0.5-1µg/kg as an infusion over 10-20 minutes prior to LETI, in addition to low dose opioids, decrease the response to LETI and improve haemodynamics. The risk of hypotension and bradycardia should always be considered. A recent meta-analysis confirmed, in cardiac patients for non-cardiac surgery, perioperative Dexmedetomidine significantly increased the incidence of hypotension and bradycardia. (55) β BLOCKERS Labetolol has a combination of α and β blockade. The α blockade is specific for α 1 and non-specific for β blockade. The ratio of α1 to β blocking effect is 1:7. It has an onset of 1-5 minutes and a half-life of up to 5.5 hours. (72) Inanda et al(61) compared Labetolol (5mg and 10mg) to Lignocaine (100mg) and a placebo group in healthy patients presenting for general surgery. Labetolol 10mg ivi (+/- 0.14mg/kg) 2 minutes prior to LETI blocked the HR response better than the other 2 groups but the BP response was the same in all four groups. Chung et al (62) confirmed these findings with a larger dose of 0.4mg/kg administered 5 minutes prior to LETI. Leslie et al(63) compared doses between 0.25mg/kg to 1mg/kg. It was found that Labetalol effectively attenuated the HR and BP response in a dose dependant manner. But they also state that although the higher doses block the BP response, they are at the expense of significant post intubation hypotension. One of the main concerns of Labetalol is the prolonged duration of action. Esmolol is a cardio selective β blocker with rapid onset and offset. (72)It reaches peak blood levels in about 2 minutes and has an approximated half-life of 9 minutes.(2) Page 11 of 26 Several studies have assessed the effectiveness of Esmolol in blunting the response to LETI. As with many of the other drugs mentioned, little consensus has been reached with regards to optimal dose, time and risk of side effects in the different population groups. A recent meta-analysis(5) attempts to determine the optimal dose of Esmolol needed to minimize the response to LETI and decrease post intubation hypotension. The analysis includes 38 studies and concludes that a loading dose of 500µg/kg over 4 minutes followed by an infusion of 200-300µg/kg/min is the best approach. It also states that a dose dependant risk of hypotension is entailed during induction and its routine use is not recommended. A comment on this meta-analysis is that of the 38 studies evaluated, only 6 studies evaluated the use of Esmolol in patients with hypertension or coronary artery disease. A sub analysis could not be done as the numbers were insufficient. Nevertheless these 6 studies indicated that neither the effectiveness of the drug nor the magnitude of adverse effects were seemingly different from the studies in healthy patients. Of note is that 19 of the included studies included the use of different opioids as premedication or as part of induction. MAGNESIUM SULPHATE (MGSO4) MgSO4 is involved in several physiological processes including control of vasomotor tone, cardiac excitability and release of neurotransmitters. Through various methods it causes vasodilation and decreases release of catecholamines from the nerve terminals and adrenal gland.(56) A small but eloquent study by James et al(57) studied the effect of 60mg/kg MgSO4 pre-treatment on the cardiovascular response to LETI and catecholamine release. 16 healthy male patients were randomly allocated to a placebo group or the MgSO4 group. All patients were pre-medicated with Diazepam 10mg po 1 hour pre surgery. No opioids were used during induction. Although MgSO4 caused a slight increase in HR after injection, the increase post intubation was still less when compared to the placebo group. BP readings were significantly lower in the MgSO4 group post LETI. The study also indicated that MgSO4 can significantly attenuate catecholamine output at the time of LETI. Puri et al(58) studied the use of MgSO4 in patients with coronary artery disease presenting for CABG. A dose of 50mg/kg(n=19) was compared to Lignocaine 1mg\kg (n=17). Page 12 of 26 They concluded that MgSO4 attenuated the haemodynamic response to LETI more effectively than Lignocaine. None of the patients in the MgSO4 had significant ST changes, compared with three patients in the Lignocaine group. Panda et al(56) determined that the minimal effective dose of MgSO4 needed to attenuate the intubation response in controlled hypertensive patients was 30mg/kg. Higher dosages were associated with significant hypotension. James et al(59) compared Lignocaine (1,5mg/kg), Alfentanil (10µg/kg) and MgSO4 (40mg/kg) in hypertensive, proteinuric pregnant patients. Systolic blood pressure exceeded baseline values the first 5 min after tracheal intubation in the lignocaine group, but no mean increase in pressure occurred in the two other groups. Alfentanil caused the least change in heart rate, but resulted in significant fetal depression. In a subsequent study(60), MgSO4 40mg/kg was compared to MgSO4 30mg/kg with Alfentanil 7.5µg/kg. The conclusion was that both methods controlled the haemodynamic response satisfactorily but that the combination was superior in controlling both the BP and HR response. There was no difference in fetal outcome between the two groups. NOVEL IDEAS Gabapentin inhibits membrane voltage gated calcium channels. It is being used more frequently as an adjunct for treatment of acute post-operative pain in the setting of chronic pain. (61)(72) Fassoulaki et al(61) studied the impact of their standard analgesic regime of Gabapentin, on the haemodynamic changes during LETI. 46 ASA I-II patients scheduled for elective hysterectomy were randomly allocated to receive Gabapentin 400mg or placebo 6 hourly, starting at noon the day prior to theatre (total dose 1600mg). No other premedication was given and a standard induction was done with Propofol and Cisatracuruim. No opioids were given prior to intubation. They found that this regime attenuated the BP response but not the HR response. Kumari et al(62) studied the effect of a single dose of 900mg given 2 hours preoperatively. The only statistically significant effect was noted at the 10 minute post LETI interval. Although this study came to the conclusion that a single dose is effective in reducing the response to LETI, it is questionable since most authors agree that the response to LETI lasts a maximum of 10 minutes with the peak effect in the first few minutes. No mention is made of an anxiolytic or opioid given pre induction with Propofol 2.5mg/kg. In a similar study Bafna et al(63) found that a single dose of 1g, 1hour pre op had a statistically significant effect in controlling the BP and HR. Once again this study was conducted in healthy patients for elective surgery. Page 13 of 26 The significant difference is that the patients were pre-medicated with Midazolam and Fentanyl and induced with Thiopentone 5mg/kg. The most convincing study of a single dose of Gabapentin is Memis et al (64). 90 healthy patients were randomised to either a placebo, Gabapentin 400mg or 800mg group administered 1 hour before surgery. No other pre medications were given and no opioids were used during induction. Patients were induced with Propofol 2mg/kg. They showed a statistically significant decrease in HR and BP, in the 800mg group, at all intervals recorded when compared to the other groups. Pregabalin is structurally but not functionally related to gamma-aminobutyric acid (GABA). It acts by inhibiting the synthesis of the neurotransmitter glutamate.(72) In a prospective study Bhawna et al(65) randomly allocated 90 healthy patients to either a placebo (group I), Pregabalin 75mg (group II) or Pregabalin 150mg (group III) group administered 1 hour pre induction. Statistically significant increases in BP post LETI were seen in group I and II while a significant decrease was seen in group III. There was no significant decrease in HR in any group. These results are confirmed by another study. Sunder et al (73) found that a single dose of Pregabalin 150mg attenuated the response to LETI in patients presenting for cardiac surgery. In contrast to Bhawna et al this study showed a statistically significant reduction in HR response to LETI. Possible reasons for this include that the Sunder trial was done in cardiac patients and a therefor a significant proportion of patients were on rate modulating medication. Another contributing factor is that the Sunder study used opioids a part of the induction. Page 14 of 26 SUMMARY OF EVIDENCE Dose Drug Lignocaine 4ml of 4% Topisolution cal 1.5mg/kg ivi 4mg/kg 2mg/kg 1.5mg/kg 120mg Alfentanil Rout e 1.5mg/kg 1.5mg/kg 30µg/kg 15µ/kg elderly Nebulised ivi ivi Aerosol ivi ivi ivi ivi Blunte Blunte d BP d HR moder ate X X X X X Page 15 of 26 No Reference effec t X 14 modera te 14 X 16 X X X 16 17 18 X X X 19,20 21 23-26 27 10µg/kg Longstandin g Treated HT Fentanyl 2µg/kg 3-5 min pre LETI 2µg/kg 5-8µg/kg Remifentanil 0.5µg/kg bolus then 0.25µg/kg/min 0.5µg/kg then 0.1µ/kg/min in HT/ elderly Sufentanil 1µg/kg 2min prior to LETI 0.1µg/kg then 0.01µg/kg/min for 5 min Clonidine 5µg/kg 60-90 pre LETI Dexmedeto 0.12µg/kg midine over 10min then 0.006µg/kg/ min 0.6µg/kg/min over 10 min 1µg/kg over 20 min 0.5µg/kg over 10 minutes, in cardiac pt Labetolol 10mg 0.4mg/kg Esmolol 500µg/kg over 4min then 200300µg/kg/min Pregabalin ivi X ivi moderate moderate 32 ivi ivi ivi X X X none X X 33,34 34-36 30 ivi X X 28,31 ivi X X 38-39 ivi X X 40,41 po moderate moderate ivi X 28 45-48 X 50 X 51 ivi X ivi moderate moderate 52 ivi moderate moderate 54 ivi ivi ivi X X moderate X 61 62 5 75mg,1 hour po pre LETI Page 16 of 26 x 65 150mg,1 hour pre op Gabapentin 400mg/6 hourly 900mg,2hour s pre LETI 1g, 1 hour pre LETI 400mg 1 hour pre LETI 800mg,1 hour pre op Magnesium 60mg/kg 30mg/kg 40mg\kg 50mg\kg X= effect on parameter po X 65,73 po X 61 po po X X X po 62 63 X po moderate moderate 64 ivi ivi ivi ivi X X X X 57 56 59-60 58 moderate moderate moderate moderate BENEFITS OF ATTENUATING THE RESPONSE Central to the question regarding the benefit of blunting the IR is the differentiation between final outcomes (death, peri-operative MI) and process outcome (ischemia,hypotension,tachycardia,arrhythmias).(2) As seen, numerous studies have been done to modify the response to LETI. They invariably report on variables such as HR, BP, rate- pressure ratio and ST changes. Most studies record this for approximately 10 minutes post LETI. Very few report on the influence these have on final outcomes. (66) Therefore, benefits of the techniques described are presumptive and we assume that by altering the haemodynamic response to LETI, we will improve or alter outcome. Both HR and BP are determinants of delivery and demand of oxygen. An increase in heart rate deleteriously affects both supply and demand of oxygen. BP is related to cardiac output (CO) and systemic vascular resistance (SVR). A change in either CO or SVR will result in a compensatory change in the other. Hypertension can therefore affect both supply and demand(66). All other organs but most important to this discussion, the brain, heart and kidneys depend on systemic pressure to maintain perfusion pressure. Therefore it is inferred that certain patients cannot tolerate the consequences of the haemodynamic response to LETI. Page 17 of 26 These would unarguably include eclamptic patients due to the risk of cerebral haemorrhage and pulmonary oedema. Other such populations would include patients with raised intra cranial pressure, patients presenting for cardiac surgery or patients with acute hypertensive urgencies/emergencies. The grey area appears when researching the benefit in patients with risk factors for cardiovascular disease but with no target organ damage presenting for noncardiac surgery. Reich et al(67)performed a retrospective sub analysis (n=797). The aim was to see if intra-operative deviations of HR and BP were associated with peri-operative mortality and morbidity. All patients were undergoing complex non cardiac surgery and controlled for the influence or pre-operative medical conditions. Deviations were defined as HR< 45 />110, MAP<55/>100mmHg and SBP<80/>160mmHg or any duration of time. The primary end-point was negative surgical outcome (NSO) including postoperative hospital stay > 10days with a morbid condition or death during the same hospitalization. There was no strong association between NSO and variations in haemodynamics in surgeries lasting less than 220 min. For surgeries lasting more than 220min there was a strong association with low MAP and increased HR. Increased HR was the stronger predictor. Increased HR and increased SBP were both strong, independent predictors of adverse outcomes in surgeries lasting more than 220 minutes. Bijker et al (68) studied the association between 1 year mortality and intra operative hypotension (IOH). This retrospective review (n=1705) included patients undergoing general and vascular surgery. Among others, the study examines the effect of hypotension, defined in 48 different ways, on mortality. After adjusting for confounding variables, the regression analysis failed to show any association between IOH and 1 year mortality. The only positive associations were between advanced age, history of hypertension, prolonged surgery and IOH. This study failed to indicate what degree and what duration of IOH can be tolerated during surgery. Monk et al (69)studied the association between anaesthetic management and one year mortality after non cardiac surgery. This study included 880 patients. Multivariate analysis indicated 3 significant predictors of 1 year mortality. One of these predictors included IOH. Systolic hypotension increased mortality risk by 1.036(RR) per minute below <80mmHg. (95 % CI 1.006-1.066) Page 18 of 26 Walsh et al(70) analysed prospectively gathered data from over 33 000 patients undergoing non cardiac surgery. They found that a MAP <55mmHg was independently associated with the development of acute kidney injury, myocardial injury and cardiac complications. This risk escalates with time spent under MAP<55mmHg but there does not appear to be any safe amount of time to spend under a MAP<55mmHg. A Cochrane review from 2013(71) had the primary objective to determine the effectiveness of pharmacological agents in preventing the morbidity and mortality resulting from the haemodynamic changes during LETI. Secondary objectives included the effect on arrhythmias and on ECG changes associated with ischemia. The review included 72 randomised controls trials that studied the effect of 32 different drugs belonging to different pharmacological classes. Only 2 trials mentioned the primary outcome of morbidity and mortality and both these trials reported no major morbidity or mortality. From this review there is no observed evidence that pharmacological agents influence morbidity or mortality. This review also suggests that the pre-treatment with pharmacological interventions is associated with a decreased risk of arrhythmias. None of the studies commented on the percentage of patients requiring treatment for the observed arrhythmias or any further consequences related to the rhythm disturbances. 31 studies included myocardial ischaemia. None of the studies examined the final outcome of intra operative evidence of ischaemia in the post-operative period. Over all, pharmacological intervention reduced the risk of myocardial ischaemia. But all the evidence came from 9 trials and therefor it should be treated with caution. Further, Local anaesthetic was the only contributor in this sub group but the analysis was dominated by a single study. β blockers were the largest contributor in this sub group analysis and showed no advantage. Once again this should be treated with caution as the studies were mostly underpowered to look for this complication. In the sub group analysis comparing high risk (17 studies) to low risk patients, treatment was effective in low risk patients but not in high risk patients. This could be due to underpowering of the studies or due to other medications not accounted for in the high risk group. Overall all the studies were underpowered to detect a reduction in the risk of ECG abnormalities. In summary, in low risk patients, pre-induction use of pharmacological agents reduces the risk of arrhythmias from 13% to 4% and appears effective in reducing the risk of myocardial ischaemia. In high risk patients pharmacological agents resulted in a reduction in the risk of arrhythmias but not in ECG evidence of ischaemia. The above summary must be viewed with the limitations discussed previously. Page 19 of 26 CONCLUSION Evidence of the hemodynamic effect to LETI has been available for more than 60 years. The precise mechanism is still being debated but the immediate physiological consequences are well documented. Numerous methods are available to attenuate this response and literarlly thousands of trials have been done to this regard. The long-term consequences and effect on morbidity and mortality of the intubation response in different surgical population groups are not well established. Therefore the benefit of attenuating this response in all patients is not clear cut. The interventions applied to blunt the response are not without complications, some of which have their own effect on morbidity and mortality. In certain high risk groups the benefit is inferred as it would be unethical to study the consequence of not blunting the response. Modification of the haemodynamic response to LETI is an admirable objective and clearly warranted in a select group of patients in whom a transient hyper-dynamic episode can lead to catastrophe. However, extending the principle of vigilant haemodynamic control to the entire peri-operative period holds more logic than tunnel vision surrounding the 2 minutes around intubation. Page 20 of 26 REFERENCES 1. KING BD, HARRIS LC,. Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anesthesia. Anesthesiology. 1951 Sep,12(5):556–66. 2. Kovac L. Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. J. Clin. Anesth. Anesth. 1996 Feb;8(1):63–79. 3. Vohra A, Kumar S, Charlton AJ,.Effect of diabetes mellitus on the cardiovascular responses to induction of anaesthesia and tracheal intubation. Br. J. Anaesth 1993 Aug [71(2):258–61. 4. Low JM, Harvey JT, Prys-Roberts C, Studies of anaesthesia in relation to hypertension. VII: Adrenergic responses to laryngoscopy. Br. J. Anaesth. [Internet]. 1986 May;58(5):471–7. 5. FIGUEREDO E and GARCIA-FUENTES E. M. Assessment of the efficacy of esmolol on the haemodynamic changes induced by laryngoscopy and tracheal intubation : A meta-analysis. Acta Anaesthesiol Scand. 2001;1(11):1011–22. 6. Simmons S, Schleich a. Airway regional anesthesia for awake fiberoptic intubation. Reg. Anesth. 2002 Mar;27(2):180–92. 7. NYSORA - The New York School of Regional Anesthesia - Regional & Topical Anesthesia for Endotracheal Intubation http://www.nysora.com/techniques/nerve-stimulator-and-surface-based-ratechniques/head-and-neck-blocka/3022-regional-topical-anesthesia-forendotracheal-intubation.html 8. Gupta A, Wakhloo R, Gupta V, Mehta A, Kapoor BB. Comparison of Esmolol and Lignocaine for Atttenuation of Cardiovascular Stress response to Laryngoscopy and Endotracheal Intubation. 2009;11(2):0–3. 9. Singh S. Cardiovascular changes after the three stages of nasotracheal intubation. Br. J. Anaesth 2003 Nov 1,91(5):667–71. 10.Shinji T, Mizutani T, Masayuki M. Hemodynamic responses to tracheal intubation with laryngoscope versus lightwand intubating device (Trachlight) in adults with normal airway. Anesth. Analg. 2002 p. 480–484. 11.Hassan HG, el-Sharkawy TY, Renck H, Mansour G, Fouda A. Hemodynamic and catecholamine responses to laryngoscopy with vs. without endotracheal intubation. Acta Anaesthesiol. Scand. 1991 p. 442–7. 12.Shribman AJ, Smith G, Achola KJ. Cardiovascular and catecholamine responses to laryngoscopy with and without tracheal intubation. Br. J. Anaesth. 1987 p. 295–9. 13. Perkins ZB, Gunning M, Crilly J, Lockey D, O’Brien B. The haemodynamic response to pre-hospital RSI in injured patients. Injury, Elsevier Ltd; 2013 May 44(5):618–23. Page 21 of 26 14. Hamill JF, Bedford RF, Weaver DC, Colohan AR. Lidocaine before endotracheal intubation: intravenous or laryngotracheal? Anesthesiology , 198155(5):578–81. Available from: 15. Laurito CE, Baughman VL, Becker GL,Effects of aerosolized and/or intravenous lidocaine on hemodynamic responses to laryngoscopy and intubation in outpatients. Anesth. Analg. 1988 p. 389–92. 16. Laurito CE, Baughman VL, Becker GL, Effects of aerosolized and/or intravenous lidocaine on hemodynamic responses to laryngoscopy and intubation in outpatients. Anesth. Analg1988 Apr,67(4):389–92. 17. Miller CD, Warren SJ. IV lignocaine fails to attenuate the cardiovascular response to laryngoscopy and tracheal intubation. Br. J. Anaesth. 1990 Aug 65(2):216–9. 18. Sklar BZ, Lurie S, Ezri T, Lidocaine inhalation attenuates the circulatory response to laryngoscopy and endotracheal intubation. J. Clin. Anesth. 4(5):382–5. 19. Tam S, Chung F, Campbell M. Intravenous lidocaine: optimal time of injection before tracheal intubation. Anesth. Analg, 1987 Oct;66(10):1036–8. 20. Splinter WM, Cervenko F. Haemodynamic responses to laryngoscopy and tracheal intubation in geriatric patients: effects of fentanyl, lidocaine and thiopentone. Can. J. Anaesth. 1989 Jul;36(4):370–6. 21. Helfman SM, Gold MI, DeLisser EA, Herrington CA. Which drug prevents tachycardia and hypertension associated with tracheal intubation: lidocaine, fentanyl, or esmolol? Anesth. Analg. 1991 Apr ,72(4):482–6. 22. Woods a W, Allam S. Tracheal intubation without the use of neuromuscular blocking agents. Br. J. Anaesth. 2005 Feb;94(2):150–8. 23. Crawford DC, Fell D, Achola KJ,Effects of alfentanil on the pressor and catecholamine responses to tracheal intubation. Br. J. Anaesth. 1987 p. 707– 12. 24. Martineau RJ, Tousignant CP, Miller DR, Alfentanil controls the haemodynamic response during rapid-sequence induction of anaesthesia. Can. J. Anaesth. 1990 p. 755–61. 25. Miller DR, Martineau RJ, O’Brien H, Hull KA,.Effects of alfentanil on the hemodynamic and catecholamine response to tracheal intubation. Anesth. Analg. 1993 p. 1040–6. 26. Korpinen R, Saarnivaara L, Siren K, Sarna S. Modification of the haemodynamic responses to induction of anaesthesia and tracheal intubation with alfentanil, esmolol and their combination. Can. J. Anaesth. 1995 Apr;42(4):298–304. Page 22 of 26 27. Kirby IJ, Northwood D, Dodson ME. Modification by alfentanil of the haemodynamic response to tracheal intubation in elderly patients. A doseresponse study. Br. J. Anaesth. 1988 p. 384–7. 28. Maguire a M, Kumar N, Parker JL, Rowbotham DJ, Thompson JP. Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients. Br. J. Anaesth. 2001 Jan;86(1):90–3. 29. Thompson JP, Hall AP, Russell J, Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br. J. Anaesth. 1998 p. 467–9. 30. Hall AP, Thompson JP, Leslie N a Comparison of different doses of remifentanil on the cardiovascular response to laryngoscopy and tracheal intubation. Br. J. Anaesth. 2000 Jan;84(1):100–2. 31. Habib AS, Parker JL, Maguire AM, Rowbotham DJ, SHORT COMMUNICATION Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly. Br. J. Anaesth. 2002;88(3):430–3. 32. Channaiah VB, Chary K, Vlk JL, Low-dose fentanyl : hemodynamic response to endotracheal intubation in normotensive patients. Arch Med Sci. 2008;3(september):293–9. 33. Song H. Small-Dose Fentanyl: Optimal Time of Injection for Blunting the Circulatory Responses to Tracheal Intubation. Anesth. Analg. 1998;86:658–61. 34. Kautto UM. Attenuation of the circulatory response to laryngoscopy and intubation by fentanyl. Acta Anaesthesiol. Scand. 1982 Jun;26(3):217–21. 35. Feng CK, Chan KH, Liu KN, Or CH, Lee TY. A comparison of lidocaine, fentanyl, and esmolol for attenuation of cardiovascular response to laryngoscopy and tracheal intubation. Acta Anaesthesiol..1996 Jun 34(2):61–7. 36. Martin DE, Rosenberg H, Aukburg SJ,Low-dose fentanyl blunts circulatory responses to tracheal intubation. Anesth. Analg 1982 Aug61(8):680–4. 37. Chung F, Evans D. Low-dose fentanyl : haemodynamic re- sponse during induc- tion and intubation in geriatric patients. Can. J. Anaesth. 1985;32(6):622–8. 38. Kay B, Nolan D, Mayall R, Healy TE. The effect of sufentanil on the cardiovascular responses to tracheal intubation. Anaesthesia 1987 Apr 2013;42(4):382–6. 39. Zhang H, Guo Q. [Effect of different doses of sufentanil on stress responses to tracheal intubation in patients undergoing heart valve replacement surgery]. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 2007 Jun Page 23 of 26 40. IANNUZZI E, IANNUZZI M, CIRILLO V, VIOLA G, PARISI R, CERULLI A, et al. Peri-intubation cardiovascular response during low dose remifentanil or sufentanil administration in association with propofol TCI: A double blind comparison. Minerva Anestesiol. Minerva medica; 2004 70(3):109–15. 41. Casati A, Fanelli G. sfenta adult.pdf. Eur. J. Anaesthesiol. 2001;18:108–12. 42. Xue FS, Xu YC, Liu Y, Yang QY, Liao X, Liu HP, et al. Different small-dose sufentanil blunting cardiovascular responses to laryngoscopy and intubation in children: a randomized, double-blind comparison. Br. J. Anaesth. 2008 May 100(5):717–23. 43. Xue FS, Liu KP, Liu Y, Xu YC, Assessment of small-dose fentanyl and sufentanil blunting the cardiovascular responses to laryngoscopy and intubation in children. Paediatr. Anaesth. [Internet]. 2007 Jun [cited 2013 Nov 26];17(6):568–74. Available from: 44. Ghignone M, Noe C, Calvillo O, Quintin L. Anesthesia for ophthalmic surgery in the elderly: the effects of clonidine on intraocular pressure, perioperative hemodynamics, and anesthetic requirement. Anesthesiology. 1988 p. 707–16. 45. Ghignone M, Quintin L, Duke PC, Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology. 1986 p. 36–42. 46. Majumdar S. Comparative evaluation of oral clonidine and midazolam as premedication on preoperative sedation and laryngoscopic stress response attenuation for the patients undergoing general anaesthesia. Int. J. Med. public Heal. 2013;3(3):200–7. 47. Gupta K, Sharma D, Gupta PK. Oral premedication with pregabalin or clonidine for hemodynamic stability during laryngoscopy and laparoscopic cholecystectomy: A comparative evaluation. Saudi J. Anaesth. [Internet]. 2011 Apr [cited 2013 Nov 26];5(2):179–84. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3139312&tool=pmc entrez&rendertype=abstract 48. Laisalmi M, Koivusalo a M, Valta P, Tikkanen I, Lindgren L. Clonidine provides opioid-sparing effect, stable hemodynamics, and renal integrity during laparoscopic cholecystectomy. Surg. Endosc. 2001 Nov 15(11):1331–5. 49. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992 Dec77(6):1134–42. 50. Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth. Analg. 1992 Dec;75(6):940–6. Page 24 of 26 51. Jaakola ML, Ali-Melkkilä T, Kanto J,. Dexmedetomidine reduces intraocular pressure, intubation responses and anaesthetic requirements in patients undergoing ophthalmic surgery. Br. J. Anaesth.1992 Jun 68(6):570–5. 52. Bajwa SJS, Kaur J, Singh A, Parmar S, Attenuation of pressor response and dose sparing of opioids and anaesthetics with pre-operative dexmedetomidine. Indian J. Anaesth 2012 Mar 56(2):123–8. 53. Menda F, Köner O, Sayin M, Türe H. Dexmedetomidine as an adjunct to anesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing fast-track CABG. Ann. Card. anaesthesias Card. Anaest,2010,13(1):16–21. 54. Sulaiman S, Karthekeyan RB, Vakamudi M, The effects of dexmedetomidine on attenuation of stress response to endotracheal intubation in patients undergoing elective off-pump coronary artery bypass grafting. Ann. Card. Anaesth, 2012 ,15(1):39–43. 55.Biccard BM, Goga S, de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia,2008 Jan];63(1):4–14. 56. Panda NB, Bharti N, Prasad S. Minimal effective dose of magnesium sulfate for attenuation of intubation response in hypertensive patients. J. Clin. Anesth. [Internet]. Elsevier; 2013 Mar;25(2):92–7. 57. James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth. Analg. 1989 Jun;68(6):772–6. 58. Puri GD, Marudhachalam KS, Chari P, Suri RK. The Effect of Magnesium Sulphate on Hemodynamics and Its Efficacy in Attenuating the Response to Endotracheal Intubation in Patients with Coronary Artery Disease. Anesth. Analg. 1998;87(4):808–11. 59. Allen RW, James MF, Uys PC. Attenuation of the pressor response to tracheal intubation in hypertensive proteinuric pregnant patients by lignocaine, alfentanil and magnesium sulphate. Br. J. Anaesth, 1991 Feb,66(2):216–23. 60. Ashton WB, James MF, Janicki P, Uys PC. Attenuation of the pressor response to tracheal intubation by magnesium sulphate with and without alfentanil in hypertensive proteinuric patients undergoing caesarean section. Br. J. Anaesth 1991 Dec 67(6):741–7. 61. Fassoulaki a, Melemeni a, Paraskeva a, Petropoulos G. Gabapentin attenuates the pressor response to direct laryngoscopy and tracheal intubation. Br. J. Anaesth, 2006 Jun,96(6):769–73 62. Kumari I, Pathania VS. A Prospective Randomised Double-Blind Placebo Controlled Trial of Oral Gabapentin in Attenuation of Haemodynamic Responses During Laryngoscopy and Tracheal Intubation. J. Anaesthesiol. Clin. Pharmacol. 2009;25(4):439–43. Page 25 of 26 63. Bafna U, Goyal VK, Garg A. A comparison of different doses of gabapentin to attenuate the haemodynamic response to laryngoscopy and tracheal intubation in normotensive patients. J. Anaesthesiol. Clin. Pharmacol. 2011 Jan ];27(1):43–6. 64. Memis D, Turan A, Karamanlioglu B, Tiire M. Original Article Gabapetitin reduces cardiovascular responses to laryngoscopy and tracheal intubation. Eur. J. Anaesthesiol. 2006;23(8):686–90. 65. Rastogi B, Gupta K, Gupta PK, Agarwal S, Jain M, Chauhan H. Oral pregabalin premedication for attenuation of haemodynamic pressor response of airway instrumentation during general anaesthesia: A dose response study. Indian J. Anaesth, 2012 Jan;56(1):49–54. 66.Thomson I. Editorial The haemodynamic response to intubation : a perspective La rrponse h6mo- dynamique a l ’ intu- bation : un perspective. Can. J. Anaesth. 1989;36(4):367–9. 67. Reich DL, Bennett-guerrero E, Bodian CA, Hossain S, Winfree W, Krol M. Intraoperative Tachycardia and Hypertension Are Independently Associated with Adverse Outcome in Noncardiac Surgery of Long Duration. Anesth. Analg. 2002;95(2):273–7. 68. Bijker JB, van Klei WA, Vergouwe Y, Eleveld DJ, van Wolfswinkel L, Moons KGM, et al. Intraoperative hypotension and 1-year mortality after noncardiac surgery. Anesthesiology 2009 Dec;111(6):1217–26. 69. Monk TG, Saini V, Weldon BC, Sigl JC. Anesthetic management and one-year mortality after noncardiac surgery. Anesth. Analg. 2005 Jan100(1):4–10. 70. Walsh M, Devereaux P, Rodseth RN, Relationship between Intraoperative Mean Arterial Pressure and Clinical Outcomes after Noncardiac Surgery. Anesthesiology. 2013;119(3):507–15. 71. Khan F, Ullah H. Pharmacological agents for preventing morbidity associated with the haemodynamic response to tracheal intubation ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Cochrane Database Syst. Rev. 2013;(7). 72. Pharmacology for Anaesthesia and Intensive care, 3rd edition,T.E Peck,S.A Hill 73. Sundar, A,S, Kodali, R, Sulaiman, S. The effects of preemptive pregabalin on attenuation of stress response to endotracheal intubation and opioid-sparing effect in patients undergoing off-pump coronary artery bypass grafting. Annals of cardiac anaesthesia 2012,15 (1) 18-25 Page 26 of 26